Animal Health Partnering Terms and Agreements 2017 to 2026
294 animal health partnerships | Deal structures and financial benchmarks | Leading dealmakers and prospective partners | Disease and technology analysis | Contract intelligence
Animal Health Partnering Terms and Agreements 2017–2026
Understand how companies partner across the animal health industry using intelligence from 294 real-world agreements.
Animal Health Partnering Terms and Agreements 2017–2026 provides comprehensive intelligence on partnering deals involving animal health products, technologies and development programs.
Partnerships play an important role throughout the animal health industry, enabling companies to access innovation, combine research and development capabilities, secure rights to products and technologies, expand manufacturing capacity and extend commercial reach.
These relationships can take many forms, from early research and development collaborations through to licensing, manufacturing, supply, distribution and commercialization agreements.
The report brings this activity together in one resource, enabling users to understand who is partnering, which deal structures are being used, where activity is concentrated, what financial terms have been disclosed and how companies are working together across development and commercialization.
Rather than focusing on a single transaction type, the report provides a broad view of animal health partnering across veterinary medicines, vaccines, diagnostics and related animal health technologies.
It combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.
The report is designed for business development, licensing, corporate strategy, R&D, commercial strategy, competitive intelligence and legal teams involved in animal health partnering.
Understand the animal health partnering landscape
The report analyzes animal health dealmaking from 2017 to 2026, including:
-
Trends in partnering activity by year
-
Most active animal health dealmakers
-
Partnering activity by deal type
-
Therapy and disease area
-
Technology type
-
Stage of development
-
Leading deals by disclosed value
-
Financial terms where available
-
How animal health partnering strategies are evolving
This provides a market-wide view of where partnering activity is concentrated and how companies are using external relationships to develop and commercialize animal health innovation.
Compare different animal health partnership models
Animal health partnerships can be structured in many different ways according to the product, technology, development stage, market opportunity and capabilities of the parties.
The report enables users to investigate multiple approaches, including:
-
Research and development collaborations
-
Licensing agreements
-
Development partnerships
-
Manufacturing and supply arrangements
-
Distribution agreements
-
Commercialization partnerships
-
Other multi-component transactions
This makes it possible to compare alternative partnering routes rather than considering individual agreement types in isolation.
Benchmark animal health deal financials
The report provides dedicated analysis of disclosed financial terms across animal health partnering transactions, including:
-
Headline deal values
-
Upfront payments
-
Milestone payments
-
Royalty rates
Users can investigate the individual transactions behind these benchmarks to understand the circumstances surrounding the disclosed economics.
This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
Financial benchmarks are most useful when interpreted alongside the structure, development stage, rights and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
Identify leading animal health dealmakers and prospective partners
The report identifies the most active animal health dealmakers and provides company-level transaction histories that enable users to investigate their previous partnering activity.
This can help users identify:
-
Companies actively seeking external opportunities
-
Prospective licensing and collaboration partners
-
Organizations repeatedly active in particular animal health areas
-
Companies with demonstrated interest in specific technologies
-
Dealmakers active at relevant stages of development
-
Potential commercial, distribution or development partners
-
Competitors pursuing similar external innovation strategies
Previous transaction activity provides useful evidence of where individual companies have demonstrated an appetite for external partnering.
Understand where animal health partnering activity is concentrated
The report analyzes animal health transactions by:
-
Deal type
-
Therapy or disease area
-
Technology type
-
Stage of development
-
Company
This enables users to identify areas attracting partnering activity and focus on the subset of transactions most relevant to a particular product, technology or strategic objective.
Understand how animal health agreements are structured
Depending on the transaction and available disclosure, users can investigate areas including:
-
Rights granted and retained
-
Research and development responsibilities
-
Licensing scope
-
Exclusivity
-
Geographic and territorial rights
-
Intellectual property
-
Development and regulatory obligations
-
Manufacturing and supply
-
Distribution and commercialization responsibilities
-
Financial consideration
-
Milestones and royalties
-
Governance
-
Term and termination provisions
These real-world examples provide useful reference points when considering how a new animal health partnership might be structured.
Learn from real-world contract documents
Where publicly available, the report provides access to underlying contract documents for selected animal health transactions.
These agreements can provide substantially more detail than company announcements alone, enabling users to examine how partners have documented matters including:
-
Scope of rights
-
Intellectual property
-
Development obligations
-
Exclusivity and territory
-
Financial terms
-
Milestone triggers
-
Royalty provisions
-
Manufacturing and supply
-
Commercialization responsibilities
-
Termination and continuing rights
For teams preparing or negotiating an animal health transaction, access to real agreement language provides valuable insight into how comparable partnerships have been structured in practice.
Comprehensive animal health deal directory
The report includes a comprehensive directory of 294 animal health partnering deals, providing a focused resource for identifying relevant precedent transactions and companies.
Deals can be investigated by:
-
Company
-
Stage of development
-
Deal type
-
Therapy or disease area
-
Technology type
-
Contract availability
Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
Who should use this report?
Business Development and Licensing teams
Identify comparable animal health transactions, prospective partners and relevant agreement structures.
Animal Health Companies
Benchmark partnering activity, investigate potential partners and understand how peer companies are accessing external products and technologies.
Pharmaceutical and Biotechnology Companies
Understand partnering activity in animal health and identify organizations actively developing and commercializing veterinary products and technologies.
Companies Seeking Animal Health Partners
Identify organizations with demonstrated interest in relevant products, technologies, disease areas and stages of development.
Corporate and R&D Strategy teams
Track how companies are using external partnerships to access innovation and build animal health portfolios.
Commercial and Market Strategy teams
Investigate distribution, commercialization and other partnerships used to extend the reach of animal health products.
Competitive and Market Intelligence teams
Analyze activity by company, technology, disease area, stage and transaction type to understand evolving strategic priorities.
Legal and Transaction teams
Review publicly available agreements and precedent structures to support transaction preparation and negotiation.
Turn market-wide animal health intelligence into company-specific insight
For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
The briefing applies the underlying animal health deal intelligence to the customer's own products, technologies, portfolio or partnering objectives.
Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, deal structures, development-stage analysis, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.
Key Benefits
✔ Benchmark against 294 animal health partnerships – Access a focused body of real-world transactions spanning research, licensing, development, manufacturing, distribution, commercialization and other agreement structures.
✔ Compare multiple partnership models in one resource – Understand how animal health companies use different deal structures according to the product, technology, development stage and strategic objective.
✔ Benchmark disclosed financial terms – Analyze headline values, upfront payments, milestones and royalty rates and investigate the individual transactions behind the benchmarks.
✔ Identify prospective partners and leading dealmakers – Discover animal health companies with demonstrated interest in relevant disease areas, technologies, products and stages of development.
✔ Track where animal health partnering activity is concentrated – Analyze transactions by deal type, therapy or disease area, technology type, development stage and company.
✔ Find relevant comparable transactions – Narrow the wider dataset to agreements involving similar products, technologies, development stages and transaction structures.
✔ Learn from real contract documents – Where publicly available, review underlying agreements to understand how rights, financial terms, responsibilities and other negotiated provisions have been documented.
✔ Apply the intelligence to your own animal health strategy – Qualifying customers may also be eligible for a Customized Executive Partnering Briefing focused on their own products, technologies, prospective partners or transaction objectives.
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in animal health dealmaking
2.1. Introduction
2.2. Animal health partnering over the years
2.3. Most active animal health dealmakers
2.4. Animal health partnering by deal type
2.5. Animal health partnering by therapy area
2.6. Animal health partnering by technology type
2.7. Deal terms for animal health partnering
2.7.1 Animal health partnering headline values
2.7.2 Animal health deal upfront payments
2.7.3 Animal health deal milestone payments
2.7.4 Animal health royalty rates
Chapter 3 – Leading animal health deals
3.1. Introduction
3.2. Top animal health deals by value
Chapter 4 – Most active animal health dealmakers
4.1. Introduction
4.2. Most active animal health dealmakers
4.3. Most active animal health partnering company profiles
Chapter 5 – Animal health contracts dealmaking directory
5.1. Introduction
5.2. Animal health contracts dealmaking directory
Chapter 6 – Animal health dealmaking by technology type
Appendices
Appendix 1 – Animal health deals by company A-Z
Appendix 2 – Animal health deals by stage of development
Appendix 3 – Animal health deals by deal type
Appendix 4 – Animal health deals by therapy area
Appendix 5 – Deal type definitions
Appendix 6 – Further reading
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Animal health partnering since 2017
Figure 2: Active animal health dealmaking activity since 2017
Figure 3: Animal health partnering by deal type since 2017
Figure 4: Animal health partnering by disease type since 2017
Figure 5: Animal health partnering by technology type since 2017
Figure 6: Animal health deals with a headline value
Figure 7: Animal health deals with an upfront value
Figure 8: Animal health deals with a milestone value
Figure 9: Animal health deals with a royalty rate value
Figure 10: Top animal health deals by value since 2017
Figure 11: Most active animal health dealmakers since 2017
Pricing options
- $3,995: single-user
- $5,995: multi-user
- $7,995: corporate/enterprise license
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Biopharma Research Ltd based in County Durham, United Kingdom. We have been trading successfully online since 2012 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
About Current Partnering
A definitive, evidence-based approach to dealmaking intelligence
Current Partnering is the industry-leading provider of pharmaceutical and biotech dealmaking intelligence, delivering a clear, structured, and evidence-based view of how partnerships are designed, negotiated, and executed in practice.
Our reports combine comprehensive deal coverage, structured data analysis, and contract-level insight, enabling a deeper understanding of how financial terms, rights, and responsibilities are defined across real-world transactions.
All reports are updated every six months, ensuring users have access to the latest deal activity, trends, and market developments.
Our methodology
Built on a continuously updated proprietary database
All analysis is underpinned by Current Agreements, our proprietary deals and alliances database which is updated daily by our analysts as new transactions are announced globally.
Deal records are continuously reviewed and enriched as additional information becomes available, ensuring accuracy, completeness, and relevance.
Comprehensive and verifiable data sourcing
Deal data is sourced from publicly available industry disclosures, including:
- Company press releases and announcements
- SEC filings and equivalent regulatory disclosures
- Company and investor presentations
- Conference materials and company websites
All sources are captured and referenced, enabling full transparency and user verification.
Broad coverage across deal types and structures
Current Partnering provides comprehensive coverage across a wide range of deal types, including but not limited to:
- Licensing and co-development
- Research and collaborative R&D
- Manufacturing, supply, and distribution
- Commercialisation and co-promotion
- Equity investments, joint ventures, and asset transactions
- Options, royalties, and financing agreements
This breadth ensures a complete view of how partnerships are structured across the life sciences sector.
Structured, standardised analysis
Every deal is analysed using a consistent framework, capturing (where disclosed):
- Financial terms — including upfront payments, milestones, and royalties
- Rights allocation — development, manufacturing, and commercialization responsibilities
- Deal structure — exclusivity, territorial scope, and agreement type
- Contractual provisions — clauses defining risk, control, and value-sharing
Each deal record is fully categorised, including data fields such as:
- Therapy area and technology type
- Stage of development
- Asset type and deal components
- Geographic scope and exclusivity
- Source documentation, including press releases and SEC filings
Financial normalisation for comparability
All financial values are standardised to USD using the exchange rate at the time of deal announcement, enabling consistent comparison of deal terms across geographies.
Contract-level insight
Where available, reports include direct access to underlying agreement documents, providing visibility into how deals are constructed in practice.
This enables users to understand:
- How financial mechanisms are defined and triggered
- How responsibilities are operationalised between parties
- How flexibility, risk, and control are allocated within agreements
Designed for real-world application
Current Partnering reports are built to support business-critical decision-making across the life sciences ecosystem, including:
- Pharmaceutical and biotech companies — benchmarking deals, structuring transactions, and supporting licensing strategy
- Investment firms and venture capital — assessing deal benchmarks, valuation expectations, and partner behaviour
- Advisory, legal, and consulting firms — supporting client engagements with real-world precedent and contract-level insight
Common use cases include:
- Benchmarking comparable transactions
- Supporting valuation and deal structuring
- Preparing for negotiations
- Evaluating potential partners
- Informing internal strategy with real-world evidence
A trusted industry reference
With a long track record in the sector, Current Partnering is relied upon by leading pharmaceutical companies, emerging biotechs, investors, and advisory firms as a trusted source of dealmaking intelligence.
By combining proprietary data, rigorous methodology, and contract-level insight, our reports provide a reliable and authoritative foundation for understanding how deals are structured, negotiated, and valued.
